Search Results
Your search for ,had matches 18483 pages
Showing 9751 - 9800Mogamulizumab Improves Progression-Free Survival vs Vorinostat in Cutaneous T-Cell Lymphoma
As reported by Youn H. Kim, MD, of Stanford Cancer Institute, Stanford University School of Medicine, and colleagues in The Lancet Oncology, the phase III MAVORIC trial showed that the anti-C-C chemokine receptor 4 (CCR4) monoclonal antibody mogamulizumab (Poteligeo) significantly improved...
Rituximab/Lenalidomide vs Rituximab/Chemotherapy in Advanced Untreated Follicular Lymphoma
In the phase III RELEVANCE trial reported in The New England Journal of Medicine by Franck Morschhauser, MD, PhD, of The University of Lille, Centre Hospitalier Universitaire Lille, France, and colleagues, no difference in the complete response rate or interim progression-free survival was found...
Osimertinib in First-Line Treatment of EGFR-Mutant Metastatic NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. In April 2018, osimertinib (Tagrisso) was approved for...
Strategies for Using Anticoagulation Therapy in Patients With Cancer
Although approximately 20% to 30% of patients with cancer will develop venous thromboembolism (VTE), clinicians continue to debate strategies for pharmacologic treatment and prevention.1 At the 2018 Debates and Didactics in Hematology and Oncology Conference, held on Sea Island, Georgia, Christine...
Neuroendocrine Tumors: New Data, New Options
Because neuroendocrine tumors are not one disease but a continuum of diseases, ranging from well-differentiated tumors to poorly differentiated and small cell tumors, treatment approaches can vary greatly. At the 2018 Debates and Didactics in Hematology and Oncology conference, held on Sea Island,...
Beat AML Trial Seeking to Change Treatment Paradigm
The Beat AML Master Clinical Trial seeks to change the treatment paradigm and outcomes in acute myeloid leukemia (AML) by personalizing therapy and ultimately facilitating the approval of novel targeted agents. Co-investigator William Blum, MD, of the Winship Cancer Institute at the Emory...
Bacterial Therapy Tolerable, Shows Early Activity in Patients With Advanced Solid Tumors
A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to data presented at the CRI-CIMT-EATI-AACR...
High Levels of Fertility-Related Hormone May Be Linked to Increased Breast Cancer Risk
Having high levels of anti-Müllerian hormone (AMH)—a hormone that indicates the size of a woman’s ovarian reserve—before menopause may be associated with an increased risk of breast cancer, a study by Ge et al in the International Journal of Cancer found. In a major study,...
Thermal Ablation vs Stereotactic Radiotherapy in Early-Stage NSCLC
Thermal ablation is a safe, effective treatment for early-stage non–small cell lung cancer (NSCLC), with comparable results to traditional stereotactic radiotherapy, according to a study published by Uhlig et al in the journal Radiology. The results show that ablation may be an effective ...
FDA Approves Once-Weekly Carfilzomib in Combination With Dexamethasone for Relapsed or Refractory Multiple Myeloma
Today, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) to expand the prescribing information for carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with relapsed or...
Patient-Partnered Genomics Study Identifies Immunotherapy as a Potential Treatment for Angiosarcomas
Angiosarcoma of the head, face, neck, or scalp is a rare cancer associated with high rates of local recurrence, distant metastasis, and poor prognosis. Because angiosarcoma is so rare, it is difficult to conduct large-scale research in the cancer. To address this issue, the Broad Institute of MIT...
Cancer Vaccine Shows Clinical Benefit in Phase I Study of Patients With HER2-Positive Cancers
A preclinical study showing that a vaccination with a recombinant adenovirus expressing a truncated ErbB-2 antigen can cure advanced established murine breast cancer as well as extensive established metastatic lung cancer led to the launch of a small phase I study investigating a therapeutic cancer ...
FDA Approves Cemiplimab-rwlc for Metastatic Cutaneous Squamous Cell Carcinoma
On September 28, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (SCC) or locally advanced cutaneous SCC who are not candidates for curative surgery or...
WCLC 2018: SWOG Study Shows Survival Benefit in Study Population of Women With NSCLC Compared to Males, Regardless of Smoking History
Women diagnosed with non–small cell lung cancer (NSCLC) live longer than their male counterparts, according to the results of a SWOG study presented by Kathy Albain, MD, the Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine, at the...
WCLC 2018: Comprehensive Genomic Profiling Aids in Identifying Personalized Therapeutic Options
Study findings demonstrated that comprehensive genetic profiling is a useful tool in directing patient care, identifying targeted therapies, and enrolling patients in clinical trials. Kimberly Rohan, MS, APN, AOCNP®, a nurse practitioner at the Edward Cancer Center in Naperville, Illinois,...
WCLC 2018: Poziotinib in Stage IV NSCLC With Genetic Mutations
Findings presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC) showed poziotinib demonstrates clinical activity among patients with stage IV NSCLC with genetic mutations that have previously not responded to treatment....
FDA Approves Dacomitinib for Metastatic Non–Small Cell Lung Cancer
On September 27, 2018, the U.S. Food and Drug Administration (FDA) approved dacomitinib tablets (Vizimpro) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution...
Health Resource Utilization and CNS Metastases in EGFR-Mutant Advanced NSCLC
In a single-center study reported in the Journal of Oncology Practice, Chooback et al found that central nervous system (CNS) metastases are frequent in patients with EGFR-mutant advanced non–small cell lung cancer (NSCLC) and are associated with increased health resource...
Pazopanib in Treatment of von Hippel-Lindau Disease
In a single-center phase II trial reported in The Lancet Oncology, Jonasch et al found evidence of activity of pazopanib in the treatment of patients with von Hippel-Lindau disease. Study Details The study involved 31 eligible adult patients with clinical manifestations of von Hippel-Lindau...
WCLC 2018: Smoking Cessation Services Widely Accepted During Lung Cancer Screening
A recent study found that smoking cessation services offered at the time of lung cancer screening had a high acceptance rate by current smokers. William Evans, MD, FRCPC, Professor Emeritus, McMaster University Department of Oncology, and clinical advisor, Smoking Cessation, Cancer Care Ontario,...
WCLC 2018: Outdoor Air Pollution Exposure and Lung Cancer in Female Never-Smokers
Findings from a recent study demonstrate that female patients with lung cancer who have never smoked have significantly greater exposure rates to outdoor air pollution than female patients with lung cancer who have a history of smoking. Renelle L. Myers, MD, FRCPC, of the British Columbia Cancer...
High-Dose Chemotherapy and Autologous SCT vs Standard Chemotherapy in Localized High-Risk Ewing Sarcoma
As reported in the Journal of Clinical Oncology by Whelan et al, combined trials (EURO-EWING99 and Ewing-2008) have shown evidence of improved outcomes with high-dose therapy with busulfan and melphalan (BuMel) and autologous stem cell transplant (SCT) vs standard chemotherapy with vincristine,...
Overall Survival With Encorafenib Plus Binimetinib vs Vemurafenib in Advanced BRAF-Mutant Melanoma
As reported in The Lancet Oncology by Dummer et al, the phase III COLUMBUS trial has shown a significant improvement in overall survival with the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib vs vemurafenib in patients with advanced BRAF V600–mutant melanoma. ...
WCLC 2018: ALTA-1L Trial: Brigatinib vs Crizotinib in Advanced ALK-Positive NSCLC
As reported at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (Abstract PL02.03) and in the The New England Journal of Medicine by Camidge et al, an interim analysis of the phase III ALTA-1L trial has shown improved progression-free...
FDA Approves Duvelisib for Adult Patients With Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
On September 24, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to duvelisib (Copiktra) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In addition, duvelisib...
David J. Sugarbaker, MD, Pioneer in Thoracic Surgery, Mesothelioma, Dies at 65
DAVID J. SUGARBAKER, MD, was an internationally recognized thoracic surgeon who specialized in the treatment of mesothelioma and complex thoracic cancers. To be recognized as first in a medical finding or procedure is a rare honor; Dr. Sugarbaker received that honor twice, being the first to...
FDA Approves Moxetumomab Pasudotox-tdfk for the Treatment of Hairy Cell Leukemia
ON SEPTEMBER 13, 2018, the U.S. Food and Drug Administration (FDA) approved moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies,...
TGFβ Polymorphism and Radiation-Induced Fibrosis in Breast Cancer
In an analysis reported in JAMA Oncology, Benjamin D. Smith, MD, of the Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, and colleagues found that a single nucleotide polymorphism (C−509T) in the transforming growth factor β1 (TGFβ1) gene was associated with...
Triplet Combination for Advanced Anal Squamous Cell Carcinoma
In a French phase II trial reported in The Lancet Oncology, Stefano Kim, MD, of the Department of Oncology, University Hospital of Besancon, and colleagues found that treatment with docetaxel, cisplatin, and fluorouracil (DCF) was active in patients with metastatic or unresectable locally...
Neoadjuvant Therapy, Changes in Body Composition, and Resectability in Pancreatic Cancer
In a retrospective cohort study reported in JAMA Surgery, Carlos Fernández-del Castillo, MD, of the Department of Surgery, Massachusetts General Hospital, Harvard Medical School, and colleagues found that neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma was associated with...
Expect Questions About Genetic Testing for Breast Cancer
A STUDY finding that pathogenic variants in 5 genes are associated with a high risk of triple-negative breast cancer and a 20% lifetime risk for overall breast cancer1 may increase interest in genetic testing. “This is the first study to establish which genes are associated with high lifetime risks ...
Cancer Doesn’t Frighten Me
In the fall of 2009, I suddenly went from being a healthy, physically active 47-year-old to a patient with stage IV non–small lung cancer (NSCLC), with a 5-year survival rate of less than 5%. A never-smoker, I had attributed a persistent cough I’d been having to the change in the season. And why...
A Journey Through the Immune System
Although the basic concept of using the body’s immune defense mechanisms to fight cancer has been around for centuries, the idea of using immunotherapy in cancer, in general, returned to prominence when Dr. Thomas Burnet first proposed the theory of cancer immunosurveillance in 1957. Despite...
Pertuzumab in Adjuvant Treatment of HER2-Positive Breast Cancer
AT THE END OF 2017, pertuzumab (Perjeta) was granted regular approval for use in combination with trastuzumab (Herceptin) and chemotherapy as adjuvant treatment of patients with HER2- positive early breast cancer at high risk of recurrence.1,2 Supporting Efficacy Data APPROVAL WAS BASED on...
Educating Nurse Practitioners on the Care of Older Patients With Cancer in a Comprehensive Cancer Center
To expose future practitioners to the special challenges of treating cancer in older patients, the Geriatrics Service at Memorial Sloan Kettering Cancer Center (MSK) has developed a clinical education model for nurse practitioner students. Why Geriatric Oncology? GIVEN THE aging population, my...
Brave Journey Home
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Abiraterone Acetate Plus Prednisone in High-Risk Metastatic Castration-Sensitive Prostate Cancer
IN EARLY 2018, abiraterone acetate tablets (Yonsa, Zytiga) in combination with prednisone was approved for the treatment of metastatic high-risk castration-sensitive prostate cancer.1,2 Supporting Efficacy Data APPROVAL WAS BASED on findings from the phase III LATITUDE trial, in which 1,199...
2018 Quality Care: Few Women With Breast Cancer Discuss Costs With Physicians Before Beginning Treatment
Findings from a new study reveal that while many women with breast cancer experience significant financial burden and most prefer to discuss the cost of their cancer care before beginning treatment, few are having conversations about treatment costs with their cancer care teams. These findings will ...
2018 Quality Care: Opioid Deaths Are 10 Times Less Likely to Occur in Patients With Cancer Compared to the General Population
According to the U.S. Department of Health and Human Services, in 2016, over 42,000 Americans died from opioid overdose, making the epidemic a top public health concern. Although opioids are commonly used for cancer-associated pain, the risks for overdose in patients with cancer were unknown. A...
2018 Quality Care: Older Patients With Advanced Cancer Experiencing Financial Difficulties Have Worse Quality of Life and Mental Health
Older patients with advanced cancer experiencing financial toxicity due to the cost of their treatment have higher rates of severe anxiety and depression and poorer quality of life than patients who do not experience financial hardship. In addition, for those patients having financial difficulty,...
Hyperprogressive Disease in Advanced NSCLC Treated With PD-1/PD-L1 Inhibitors
In a French study reported in JAMA Oncology, Ferrara et al found that hyperprogressive disease appeared to be more common with programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor treatment than single-agent chemotherapy among previously treated patients with...
Wally Curran, MD, FACR, FASCO, Reflects on a Career in Academic Oncology
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. Find him on Twitter @jamecancerdoc. For this installment of the Living a Full Life series, guest editor, Jame Abraham, MD,...
Origins and Genetics Associated With Mixed-Phenotype Acute Leukemia
Investigators have unraveled the origins and identified mutations associated with mixed-phenotype acute leukemia. The study, published by Alexander et al in Nature, potentially lays the foundation for more effective treatment of patients with this high-risk cancer. Mixed-phenotype acute...
Avelumab Plus Axitinib in Previously Untreated Patients With Advanced Kidney Cancer
The results of the pivotal phase III JAVELIN Renal 101 study—which evaluated avelumab (Bavencio) in combination with axitinib (Inlyta) compared with sunitinib (Sutent) as initial therapy for patients with advanced renal cell carcinoma—were recently announced. As part of a planned...
Outcomes Associated With Mutation Persistence After HSCT for Myelodysplastic Syndrome
In a single-institution study reported in The New England Journal of Medicine, Duncavage et al found that mutation clearance after allogeneic hematopoietic stem cell transplantation (HSCT) was associated with better outcomes in patients with myelodysplastic syndrome. Study Details The study...
Use of Patient-Reported Outcomes Version of CTCAE in Rectal Cancer Trial
As reported in the Journal of Clinical Oncology, Basch et al established the feasibility of using the National Cancer Institute patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in the setting of a multicenter clinical trial in locally advanced...
Are E-Cigarettes a Dangerous Alternative to Traditional Cigarettes?
Several studies published earlier this year present preliminary but compelling evidence that electronic cigarettes, also known as e-cigarettes, which deliver nicotine through aerosols without burning tobacco, may pose serious health consequences to users, including cardiovascular disease and...
New Laws Limiting Opioid Prescriptions Create Undue Barriers for Patients With Cancer and Cancer Survivors
Among other policy responses to the growing opioid epidemic, many states have enacted legislation that limits the duration or amount of opioid prescriptions issued by physicians. Although, it is clear we need strong measures to mitigate widespread overuse and misuse of opioids. These...
CAR T-Cell Therapy for CLL
A pair of new studies from researchers at the Abramson Cancer Center of the University of Pennsylvania are shedding light on why patients with advanced chronic lymphocytic leukemia (CLL) respond or do not respond to chimeric antigen receptor (CAR) T-cell therapy. Although CAR T-cell therapy is...
Maintenance Therapy for Metastatic Colorectal Cancer: Benefit Seen With Panitumumab Combination
Although the optimal approach to maintenance is not definitive in patients with metastatic colorectal cancer who have undergone chemotherapy-based induction with anti–endothelial growth factor receptor (EGFR) agents, the phase II VALENTINO trial showed that anti-EGFR maintenance therapy with...
